Kaveh Karimzad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaveh Karimzad has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Anita Deswal
Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
2 shared publications - Bharat K. Kantharia
Cardiovascular and Heart Rhythm Consultants Icahn School of Medicine at Mount Sinai New York New York USA
2 shared publications - Cezar Iliescu
University of Texas MD Anderson Cancer Center
2 shared publications Juhee Song
2 shared publications- Nicolas L. Palaskas
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2 shared publications - Abdul Hakeem
Robert Wood Johnson Hospital, Rutgers University, New Brunswick, NJ 08901, USA
1 shared publication
Latest Publications
- 15 May 2026
- Published by Springer Nature
- p. 1-20
Arrhythmias in Cancer Patients
- Open Access
- 11 March 2026
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 15
Atrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates
The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and atrial cardiomyopathy.
- 11 March 2026
- Published by Radcliffe Medical Media Ltd in Arrhythmia and Electrophysiology Review
- Vol. 15
Open AccessAtrial Cardiomyopathy and Atrial Fibrillation in Different Heart Failure Substrates
The incidences of AF and heart failure (HF) have been progressively increasing worldwide. These conditions exhibit a strong interdependence, with each exacerbating the other. HF is currently classified based on left ventricular ejection fraction (EF) as HF with reduced, mid-range or preserved EF (HFrEF, HFmrEF or HFpEF, respectively). Atrial cardiomyopathy, also known as atriopathy, involves structural, architectural, contractile, or electrophysiological alterations in the atria, driven by diverse mechanisms stemming from risk factors and comorbidities, including diabetes, hypertension, ischaemic and valvular heart diseases, hypertrophic and dilated cardiomyopathies, as well as various forms of HF. Emerging evidence also implicates infiltrative cardiomyopathies (e.g. cardiac amyloidosis), certain cancers, and chemotherapeutic agents in promoting both AF and HF. This review summarises key basic and translational science findings, along with their potential clinical applications, that connect shared pathophysiological substrates between HF and atrial cardiomyopathy.
- Open Access
- 18 October 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 188-190
Cardiac resynchronization therapy in patients with cancer: A single cancer center experience
- 18 October 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 188-190
Open AccessCardiac resynchronization therapy in patients with cancer: A single cancer center experience
- Open Access
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e042937
Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice
Background: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern‐day RT are needed to guide clinical practice. Methods: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device‐related data and RT‐specific variables were collected. Statistical analyses were performed at the RT course level. Results: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8–79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter‐defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron‐producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter‐defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. Conclusions: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron‐producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.
- 2 September 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e042937
Open AccessSafety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice
Background: Radiation therapy (RT) can cause cardiac implantable electronic device (CIED) malfunction, primarily reset. Given changes in RT and CIED technologies, large observational studies examining malfunction of contemporary CIEDs during modern‐day RT are needed to guide clinical practice. Methods: Electronic medical records of all consecutive patients with CIEDs who underwent RT at a large tertiary cancer center between January 2015 and January 2022 were reviewed. All patients had CIED interrogation before and after completion of RT. Device‐related data and RT‐specific variables were collected. Statistical analyses were performed at the RT course level. Results: Over a period of 7 years, 677 patients (median age, 74 [interquartile range, 67. 8–79.2] years; 72% men) with CIEDs (498 [66%] pacemakers and 254 [34%] implantable cardioverter‐defibrillators) underwent 752 courses of RT (photon, 83.5%; proton, 10.5%; electron, 6%). Only 9 patients (1.3%) underwent CIED relocation before RT. Device malfunction was observed during 8 RT courses (1.1%), primarily soft reset with data loss. All device malfunctions were observed with neutron‐producing radiation (proton and photon >10 MV). CIED type (pacemaker or implantable cardioverter‐defibrillator), magnetic resonance imaging conditional or nonconditional system, and radiation site (thorax or nonthorax) did not show statistical differences between RT courses with reset versus no reset. No transient signal interference or oversensing due to RT was recognized by the CIED. Conclusions: CIED malfunction is a rare complication of contemporary RT, occurring primarily with neutron‐producing radiation, most of CIED malfunction cases are without serious clinical consequences. Transient signal interference and oversensing during RT does not appear to be a clinical concern in contemporary CIEDs.
- Open Access
- 12 February 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 103187
Pacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders
- 12 February 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 103187
Open AccessPacing Solutions for Immune Checkpoint Myocarditis and Associated Conduction Disorders
- Open Access
Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease
Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.
Open AccessReclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease
Background and Objectives: Cancer and coronary artery disease (CAD) often coexist. Compared to quantitative coronary angiography (QCA), fractional flow reserve (FFR) has emerged as a more reliable method of identifying significant coronary stenoses. We aimed to assess the specific management, safety and outcomes of FFR-guided percutaneous coronary intervention (PCI) in cancer patients with stable CAD. Materials and Methods: FFR was used to assess cancer patients that underwent coronary angiography for stable CAD between September 2008 and May 2016, and were found to have ≥50% stenosis by QCA. Patients with lesions with an FFR > 0.75 received medical therapy alone, while those with FFR ≤ 0.75 were revascularized. Procedure-related complications, all-cause mortality, nonfatal myocardial infarction, or urgent revascularizations were analyzed. Results: Fifty-seven patients with stable CAD underwent FFR on 57 lesions. Out of 31 patients with ≥70% stenosis as measured by QCA, 14 (45.1%) had an FFR ≥ 0.75 and lesions were reclassified as moderate and did not receive PCI nor DAPT. Out of 26 patients with p = 0.03). Conclusions: Further studies are needed to define the optimal therapeutic approach for cancer patients with CAD. Using an FFR cut-off point of 0.75 to guide PCI translates into fewer interventions and can facilitate cancer care. There was an overall reduction in mortality in patients that received a stent, suggesting increased resilience to cancer therapy and progression.
- 1 August 2018
- Published by Springer Nature
- p. 175-182
Cardiac Arrhythmia and Device Management in Patients with Cancer
- 1 August 2018
- Published by Springer Nature
- p. 175-182
Cardiac Arrhythmia and Device Management in Patients with Cancer